 |
Company History
|
Boehringer Ingelheim in the
United States
Boehringer Ingelheim, Ltd. was established in the U.S. in 1971 to market respiratory and cardiovascular medications. Boehringer Ingelheim Corporation was later established in 1986 to serve as the parent organization in the U.S. for the original pharmaceutical company and its subsequent acquisitions.
Pharmaceutical operations expanded in North America with the acquisition of Roxane Laboratories, Inc. in Columbus, Ohio in 1978, a company with expertise in cancer and palliative care.
Boehringer Ingelheim went on to achieve a major advance into the hospital market in late 1997 through the acquisition of Ben Venue Laboratories, Inc., a manufacturer and marketer of sterile injectable pharmaceuticals.
In 1999, Boehringer Ingelheim Consumer Health Care Products was established to market over-the-counter health care products.
In the animal health arena, Boehringer Ingelheim Corporation purchased the Anchor Serum Company in 1981, which became the foundation of what is today Boehringer Ingelheim Vetmedica, Inc. Boehringer Ingelheim Corporation made further inroads into the animal health business with the acquisition of Fermenta Animal Health in 1995 and the swine health company NOBL Laboratories in early 1997.
Boehringer Ingelheim Corporation first established its Fine Chemicals operations in the U.S. in the early 1970s. Today, Boehringer Ingelheim Chemicals, Inc. in Petersburg, VA is the core of Boehringer Ingelheim’s Fine Chemicals business unit in the United States.
Boehringer Ingelheim was founded in Ingelheim am Rhein (Germany) in 1885, where the corporate headquarters are located today. To learn more about our history, please visit our global website.